期刊
BRITISH JOURNAL OF CANCER
卷 85, 期 7, 页码 1032-1036出版社
NATURE PUBLISHING GROUP
DOI: 10.1054/bjoc.2001.2034
关键词
carbonyl reductase; epithelial ovarian cancer; prognosis; lymph node metastasis
类别
We have recently reported a novel function for carbonyl reductase (CR), namely, its ability to modulate the metastatic potential of malignant mouse cells. Because there are currently no data addressing a similar function for CR in human cancers, the aim Of this study was to assess a correlation between survival and metastasis, and CR level in epithelial ovarian cancer. Using anti-CR antibody, immunohistochemical staining was performed on 73 epithelial ovarian cancers, 13 borderline malignant tumours, and 25 benign ovarian tumours for a total of 111 specimens. The combined rate for strongly and weakly positive reactions for CR was 32.0% for benign tumours, 38.5% for borderline malignant tumours, and 61.6% for ovarian cancers. The CR-positive rate was 35.7% (weakly positive alone) for ovarian cancers with retroperitoneal lymph node (RLN) metastasis and 67.8% for those without RLN metastasis (P < 0.05). The 5-year survival rate was 62.7% for the patients with CR-negative cancer and 86.1% for those with CR-positive cancer (P < 0.05). The present results indicate that odecreased CR expression in epithelial ovarian cancer is associated with RLN metastasis and poor survival. (C) 2001 Cancer Research Campaign http://www.bicancer.com.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据